Identification and optimization of biosynthetic gene clusters using comparative genomics and CRISPR
Our solution leverages comparative genomics and CRISPR technology to identify and optimize biosynthetic gene clusters in bacterial strains for the production of therapeutic metabolites. This approach is ideal for developing strain-specific solutions to combat pathogens.
Overview
Our innovative approach combines comparative genomics with CRISPR technology to identify and optimize biosynthetic gene clusters (BGCs) in bacterial strains. This methodology aims to produce strain-specific metabolites with therapeutic properties, particularly in combating pathogens. By leveraging a vast collection of over 5000 bacterial isolates and extensive genomic data, we can pinpoint the genes responsible for valuable metabolite production, enabling the development of new bioactive compounds.
Technical specifications
- Comparative Genomics: We utilize large-scale genomic data to identify BGCs in bacterial strains that demonstrate desired bioactivity. Our expertise in genome analysis allows us to discern active strains from inactive ones effectively.
- CRISPR/Cas9 Technology: Rapid mutagenesis using CRISPR/Cas9 facilitates the manipulation of candidate genes, enabling the identification of essential genes for metabolite production. This method supports high-throughput capabilities, streamlining the genetic editing process.
- Bioassays and Analytical Methods: We employ bioassays to evaluate the activity of mutant strains, complemented by analytical methods such as LC-MS and NMR for metabolite identification. This ensures the accurate confirmation of bioactive compounds.
Technology readiness level
This technology is currently at TRL 5, indicating that it has been validated in relevant environments and is ready for further development and optimization in partnership with industry stakeholders.
About Commissariat à l'Énergie Atomique et aux Énergies Alternatives
CEA is a French public research organization with multi‑site campuses and large‑scale scientific infrastructure, operating across the research‑to‑industry continuum with a strong applied focus. Industry engages through co‑located technology institutes, joint laboratories, contract R&D, and access to pilot lines and test facilities on campuses embedded in the Paris‑Saclay and Grenoble innovation clusters. This model supports rapid prototyping, scale‑up, and validation under industrially relevant conditions. Research is funded by the French government alongside competitive awards from national programs and the European Commission. A tech transfer office manages IP, licensing, and venture creation with startup support on major sites.
Inquire about this partnering listing
Industry applications
delivered to your inbox.